Q-omics provides the consensus-scored MIR5186 profile across patient tissues and cancer cell-line models. MIR5186 expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR5186 is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, MIR5186 RNA expression shows 6,555 significant gene co-expression associations, with the highest sampling consensus in BRCA. Together, these results highlight BLCA, LUSC, and BRCA as cancer lineages where MIR5186 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR5186 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR5186 survival associations across molecular data types. MIR5186 RNA expression shows survival associations in the most cancer types (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR5186 RNA expression–survival associations across cancer types. High MIR5186 expression shows unfavorable associations in BLCA, LUSC, SARC, LGG and STAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR5186 RNA expression.
This table summarizes MIR5186 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR5186. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR5186 shows lower tumor expression in LUAD and higher tumor expression in LUSC. The LUSC box plot shows higher MIR5186 RNA expression in tumor versus normal tissue (log2 FC = +0.110, t-test p = .013).
This table shows molecular features associated with MIR5186 in patient tissues and cancer cell lines. In patient samples, MIR5186 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
